
U.S. Maintains India on Priority IP Watch List Amid Ongoing Disputes Over Drug Patents
Special 301 Report Highlights Persistent Tensions Between Washington and New Delhi on Pharmaceutical IP and Access to Medicines
The United States has once again placed India on its Priority Watch List in the 2024 Special 301 Report, citing ongoing concerns over India's pharmaceutical patent policies, data protection, and enforcement mechanisms. The move underscores a longstanding divide between the two nations over balancing intellectual prope…